ANTI-CARCINOMA MONOCLONAL ANTIBODIES CLINICAL TRIALS

这一项目涉及到在两种情况下使用单抗 诊断和治疗临床试验。到目前为止，已有1000多人 患者已经接受了放射性标记的B72.3肿瘤靶向治疗 在许多机构进行的研究，都有类似的发现 观察到大约70%-80%的肿瘤靶向性。精挑细选 ~(131)I单抗B72.3免疫球蛋白在体内的定位 关于结直肠癌患者注射比例的研究 每克肿瘤的单抗剂量与正常对照进行比较。 组织，从而为每个组织提供相对放射性定位化指数(RI 损伤。在肿瘤病变中，70%的RI至少为3(即3次 每克组织比正常组织更大的摄取量)。我们还进行了 确定腹膜腔给药的可行性的研究 用于肿瘤定位的放射性标记B72.3(通过伽马扫描和 直接分析活组织标本)。 一项涉及腹膜腔内给药的I期治疗试验 卵巢癌和结直肠癌患者血清中~(13)I-B72.3抗体的检测 到腹膜腔的手术正在进行中。重组/嵌合体的应用 单抗也已开始使用第二代和第三代 MAB-同位素偶联物正在计划中。

This project involves the use of monoclonal antibodies (MAbs) in both diagnostic and therapeutic clinical trials. To date, over 1,000 patients have been administered radiolabeled B72.3 in tumor-targeting studies carried out in numerous institutions, with similar findings of approximately 70-80% tumor targeting observed. The selective localization of 131-I MAb B72.3 IgG was demonstrated in biodistribution studies in colorectal cancer patients in which the percentage of injected dose of MAb per gram of each tumor was compared with that of the normal tissues, thus providing a relative radiolocalization index (RI) for each lesion. Of the tumor lesions, 70% had an RI of at least 3 (i.e., 3 times greater uptake per gram than normal tissues). We have also conducted studies to determine the feasibility of intraperitoneal administration of radiolabeled B72.3 for tumor localization (via both gamma scanning and direct analysis of biopsy specimens). A phase I therapy trial involving intraperitonel administration of l3lI-B72.3 IgG in patients with ovarian or colorectal carcinoma confined to the peritoneal cavity is in progress. The use of recombinant/chimeric MAbs has also begun and the use of second and third generation MAb-isotope conjugates are planned.